Expression of the immune checkpoint receptor TIGIT in seminoma.
Programmed Cell Death 1
T cell immunoreceptor with Ig and ITIM domains
immune checkpoint
immunotherapy
infiltrating lymphocytes
seminoma
tissue microarray
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
20
12
2018
accepted:
10
05
2019
entrez:
20
8
2019
pubmed:
20
8
2019
medline:
20
8
2019
Statut:
ppublish
Résumé
A characteristic feature of testicular seminoma is the abundance of immune cells in the tumor microenvironment, raising the possibility that immune checkpoint inhibitors may serve as a therapeutic option in these types of tumors. T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory immune checkpoint receptor in analogy to PD-1, and drugs targeting TIGIT are currently being investigated in clinical trials. Little is known about the expression of these proteins in testicular seminomas. Therefore the present study performed immunohistochemical analysis to determine the relative abundance of TIGIT and PD-1 in relation to the total CD3
Identifiants
pubmed: 31423216
doi: 10.3892/ol.2019.10428
pii: OL-0-0-10428
pmc: PMC6607271
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1497-1502Références
BJU Int. 2004 Jul;94(1):74-8
pubmed: 15217435
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Eur Urol. 2008 Mar;53(3):478-96
pubmed: 18191324
J Cancer Surviv. 2007 Mar;1(1):8-16
pubmed: 18648940
Nat Immunol. 2009 Jan;10(1):48-57
pubmed: 19011627
Semin Oncol. 2009 Oct;36(5):432-8
pubmed: 19835738
Eur Urol. 2011 Sep;60(3):516-26
pubmed: 21684072
Cancer. 2012 Feb 15;118(4):981-6
pubmed: 21792865
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
N Engl J Med. 2013 Jul 11;369(2):122-33
pubmed: 23724867
J Clin Oncol. 2014 Oct 1;32(28):3085-92
pubmed: 25024068
N Engl J Med. 2014 Nov 20;371(21):2005-16
pubmed: 25409373
Breast Cancer Res. 2014 Nov 29;16(6):488
pubmed: 25432519
Cancer Cell. 2014 Dec 8;26(6):923-937
pubmed: 25465800
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
J Clin Invest. 2015 May;125(5):2046-58
pubmed: 25866972
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Lancet Oncol. 2015 Aug;16(8):908-18
pubmed: 26115796
J Clin Invest. 2015 Nov 2;125(11):4053-62
pubmed: 26413872
Ann Oncol. 2016 Feb;27(2):300-5
pubmed: 26598537
Clin Cancer Res. 2016 Jun 15;22(12):3057-66
pubmed: 26763253
BMC Med. 2016 May 05;14:73
pubmed: 27151159
World J Urol. 2017 Aug;35(8):1167-1175
pubmed: 27449639
Trends Immunol. 2017 Jan;38(1):20-28
pubmed: 27793572
Immunol Invest. 2017 Feb;46(2):172-182
pubmed: 27819527
Immunol Rev. 2017 Mar;276(1):112-120
pubmed: 28258695
Eur J Cancer. 2017 May;76:1-7
pubmed: 28262583
Med Sci Monit. 2017 Mar 10;23:1232-1241
pubmed: 28282368
Oncotarget. 2017 Mar 28;8(13):21794-21805
pubmed: 28423520
Oncoimmunology. 2017 Mar 20;6(4):e1305535
pubmed: 28507813
Nat Biotechnol. 2017 Jun 7;35(6):487-488
pubmed: 28591107
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
Ann Oncol. 2018 Jan 1;29(1):209-214
pubmed: 29045540
Oncotarget. 2017 Aug 25;8(41):69200-69201
pubmed: 29050196
Clin Cancer Res. 2018 Feb 15;24(4):870-881
pubmed: 29217528
Eur Urol. 2019 Jan;75(1):201-203
pubmed: 30243800
BMC Cancer. 2018 Dec 4;18(1):1209
pubmed: 30514251
Dis Markers. 2019 Jan 10;2019:5160565
pubmed: 30733837
Dis Markers. 2019 May 2;2019:2532518
pubmed: 31191745
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379